ClinicalTrials.gg
CompletedNCT03251937VERITASUpdated Apr 1, 2021Results posted

Value of Multiple Modalities Using the Spectra WaveWriter Spinal Cord Stimulator System

An interventional study of Spectra WaveWriter SCS System in Chronic Pain and Back Pain, sponsored by Boston Scientific Corporation. Completed at 15 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2021-04-01.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 37 studies in Chronic Pain by Boston Scientific Corporation — 3 open to participants now, 7 under way, none of them phase 3. Chronic Pain · Boston Scientific Corporation.

Enrollment
12th of 32
97 · median 46
Started
2018
with 1 other
No phase
28 of 37
1 open now
Registered
23rd of 37
by date

Among the 37 studies in Chronic Pain by Boston Scientific Corporation, this one is the 12th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2018, is one of 28 with no phase, and was the 23rd registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 727 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

3 of the 37 studies in Chronic Pain by Boston Scientific Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Chronic Pain by Boston Scientific Corporation, or all of them as a file.
02

Study summary

To demonstrate the value of multiple modalities and sustained clinically significant pain relief in patients with chronic pain when using the Boston Scientific Spectra WaveWriter Spinal Cord Stimulator (SCS) System.

03

Conditions studied

  • Chronic Pain
  • Back Pain

Keywords

  • Chronic Pain
  • Back Pain
  • Leg Pain
  • Pain
  • Stimulation
  • Spinal Cord Stimulator
  • Implantable Pulse Generator
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Chronic pain of the trunk and/or limbs
  • 22 years of age or older at time of enrollment
  • Willing and able to comply with all protocol-required procedures and assessments/evaluations provided in English
  • Willing and capable of giving

Key Exclusion Criteria:

  • Any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment, might confound reporting of study outcomes
  • Significant cognitive impairment that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study
  • Current systemic infection, or local infection in close proximity to the anticipated surgical field
  • Breast-feeding, pregnant or planning to get pregnant during the course of the study or not using adequate
  • Previous spinal cord stimulation trial or is already implanted with an active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse generator)
  • Participating, or intends to participate, in another clinical trial that may influence the data that will be collected for this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Spinal Cord Stimulation

    Spectra WaveWriter SCS System

    Device: Spectra WaveWriter SCS System

Interventions

  • DeviceSpectra WaveWriter SCS System

    Multiple modalities of stimulation therapy

    Also known as: Spectra WaveWriter Spinal Cord Stimulation System

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline

    Time frame: 3 months post activation

07

Results

Posted Mar 16, 2020

Participant flow

Subjects were considered enrolled once informed consent was completed. Only those who met all eligibility criteria went on to receive implant and proceed in the study.

Participant flow — Overall Study
MilestoneSpinal Cord Stimulation
Started40
Completed37
Not completed3

Outcome measures

PrimaryPercentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline
Time frame:
3 months post activation
Reported as:
Count of participants · Participants
Percentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline
ParticipantsSpinal Cord Stimulation
Percentage of Subjects With 50% or Greater Reduction in Overall Pain From Baseline31

Adverse events

Collected over Adverse Events were collected through the entire study (up to 1 year post-activation) for all enrolled subjects in the study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Spinal Cord Stimulation1/97 (1%)7/97 (7.2%)0/97 (0%)
Most frequent serious events
Most frequent serious events
EventSpinal Cord Stimulation
AnginaCardiac disorders1/97
Myocardial InfarctionCardiac disorders1/97
Sinus Node DysfunctionCardiac disorders1/97
Back PainMusculoskeletal and connective tissue disorders1/97
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/97
SpondylolisthesisMusculoskeletal and connective tissue disorders1/97
Cerebrovascular AccidentNervous system disorders1/97

Baseline characteristics

Age, Continuous
Age, Continuous(years)Spinal Cord Stimulation
Mean63.2 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Spinal Cord Stimulation
Female22
Male18
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Spinal Cord Stimulation
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported40
08

Study locations

15 sites
  • Neurovations
    Napa, California 94558, United States
  • Louis J. Raso, MD, PA
    Jupiter, Florida 33477, United States
  • Florida Pain Clinic
    Ocala, Florida 34471, United States
  • Forest Health Medical Center
    Ypsilanti, Michigan 48198, United States
  • Mercy Medical Research Institute
    Springfield, Missouri 65804, United States
  • University of Rochester
    Rochester, New York 14618, United States
  • The Center for Clinical Research, LLC
    Winston-Salem, North Carolina 27103, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Western Reserve Spine and Pain Institute
    Kent, Ohio 44240, United States
  • Toledo Clinic
    Toledo, Ohio 43623, United States
  • West Chester Hospital, LLC
    West Chester, Ohio 45069, United States
  • Pacific Sports and Spine, LLC
    Eugene, Oregon 97401, United States
  • Spine Team Texas
    Rockwall, Texas 75032, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
  • Advanced Pain Management Appleton
    Appleton, Wisconsin 54913, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2019, 12 months.

Results were first posted in Mar 2020, 1 year 2 months after primary completion.

Of 83 industry-sponsored interventional studies with no phase under Chronic Pain, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 12 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2017
First posted
Aug 16, 2017
StartActual
Jan 9, 2018
Primary completionActual
Jan 9, 2019
CompletionActual
Mar 10, 2020
Results first posted
Mar 16, 2020
Last update
Apr 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03251937
Responsible party
Sponsor
First posted
Aug 16, 2017
Start date
Jan 9, 2018
Primary completion
Jan 9, 2019
Completion
Mar 10, 2020
Results posted
Mar 16, 2020
Last update
Apr 1, 2021

Study contacts

Roshini Jain
study director · Boston Scientific Corporation

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion